Symbol | Exchange | Currency |
|---|
Investing.com - Sellas Life Sciences (NASDAQ: SLS) reported first quarter EPS of $-0.47, $0.18 worse than the analyst estimate of $-0.29. Revenue for the quarter came in at $0.00...
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a...
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a...
A heavy earnings week is always a busy time for the markets, but is “busy” really the word to describe the past week?First, Let’s Talk About TwitterWell, the...
When trading opened in 2019, investors were just hoping stocks would produce a rebound from the awful fourth quarter in 2018. But Apple (NASDAQ:AAPL) nearly spoiled...
Dr. Reddy's Laboratories Ltd. (NYSE:RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago...
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in 20 or more cancer types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. The Company is also developing GFH009, a small molecule, selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
| Average | 6.00 (+257.14% Upside) |
| High | 9.00 |
| Low | 3.00 |
| Price | 1.68 |
| No. of Analysts | 4 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Strong Buy | Buy | Strong Sell |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Buy | Strong Sell |
| Summary | Sell | Strong Buy | Strong Buy | Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 125.43 | 126.00 | 123.29 | +1.08 | +0.87% | 25.17M | NASDAQ | |||
| 10.28 | 10.40 | 9.84 | +0.50 | +5.11% | 20.39M | NYSE | |||
| 37.87 | 39.41 | 37.75 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 7.12 | 7.38 | 7.07 | -0.16 | -2.20% | 716.99K | NYSE | |||
| 26.25 | 26.45 | 25.21 | +0.89 | +3.51% | 850.27K | NASDAQ | |||
| 27.60 | 27.66 | 26.67 | +0.75 | +2.79% | 922.76K | NYSE | |||
| 0.514 | 0.543 | 0.48 | -0.029 | -5.25% | 126.43K | NASDAQ | |||
| 2.43 | 2.54 | 2.43 | -0.07 | -2.80% | 921.00 | OTC Markets | |||
| 0.94 | 0.94 | 0.94 | -0.00 | -0.15% | 12.46K | OTC Markets | |||
| 4.82 | 4.82 | 4.82 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 3.00 | 3.00 | 3.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 5.00 | 5.00 | 5.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 18.63 | 18.69 | 18.615 | +0.160 | +0.87% | 24.57K | OTC Markets | |||
| 7.56 | 7.87 | 7.08 | +0.38 | +5.22% | 66.94K | NASDAQ | |||
| 1.86 | 1.90 | 1.82 | -0.50 | -21.19% | 51.35M | NASDAQ |